Last reviewed · How we verify
Permethrin Cream
Permethrin Cream, developed by the University of Oxford, is a marketed scabies treatment with a well-established presence in the dermatological segment. Its key strength lies in the strong patent protection, with the key composition patent expiring in 2028, providing a significant barrier to generic competition. The primary risk is the lack of revenue data, which may limit strategic planning and investment decisions.
At a glance
| Generic name | Permethrin Cream |
|---|---|
| Also known as | Pioletal® Plus, Primothrin®, Permethrin®, Cidal® |
| Sponsor | University of Oxford |
| Drug class | Pyrethroid [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Scabies Treatment
Common side effects
- burning and stinging
- pruritus
Key clinical trials
- Ivermectin Safety in Small Children (PHASE2)
- Better Options for Lymphatic Filariasis Treatment (PHASE3)
- Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies (PHASE2)
- Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults (PHASE3)
- Therapy for Scabies With Two Differently Concentrated Permethrin Creams (PHASE3)
- Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies (PHASE3)
- Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies (PHASE1)
- Ivermectin/ Permethrin for Scabies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Permethrin Cream CI brief — competitive landscape report
- Permethrin Cream updates RSS · CI watch RSS
- University of Oxford portfolio CI